Bone marrow mononuclear cells attenuate fibrosis development after severe acute kidney injury
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
20/10/2012
20/10/2012
2010
|
Resumo |
One of the early phases that lead to fibrosis progression is inflammation. Once this stage is resolved, fibrosis might be prevented. Bone marrow mononuclear cells (BMMCs) are emerging as a new therapy for several pathologies, including autoimmune diseases, because they enact immunosuppression. In this study we aimed to evaluate the role of BMMC administration in a model of kidney fibrosis induced by an acute injury. C57Bl6 mice were subjected to unilateral severe ischemia by clamping the left renal pedicle for 1 h. BMMCs were isolated from femurs and tibia, and after 6 h of reperfusion, 1 x 10(6) cells were administrated intraperitoneally. At 24 h after surgery, treated animals showed a significant decrease in creatinine and urea levels when compared with untreated animals. Different administration routes were tested. Moreover, interferon (IFN) receptor knockout BMMCs were used, as this receptor is necessary for BMMC activation. Labeled BMMCs were found in ischemic kidney on FACS analysis. This improved outcome was associated with modulation of inflammation in the kidney and systemic modulation, as determined by cytokine expression profiling. Despite non-amelioration of functional parameters, kidney mRNA expression of interleukin (IL)-6 at 6 weeks was lower in BMMC-treated animals, as were levels of collagen 1, connective tissue growth factor (CTGF), transforming growth factor-beta (TGF-beta) and vimentin. Protective molecules, such as IL-10, heme oxygenase 1 (HO-1) and bone morphogenetic 7 (BMP-7), were increased in treated animals after 6 weeks. Moreover, Masson and Picrosirius red staining analyses showed less fibrotic areas in the kidneys of treated animals. Thus, early modulation of inflammation by BMMCs after an ischemic injury leads to reduced fibrosis through modulation of early inflammation. Brazilian Foundation - FAPESP (Fundacao de Apoio a Pesquisa do Estado de Sao Paulo)[06/00620-5] Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Brazilian Foundation - FAPESP (Fundacao de Apoio a Pesquisa do Estado de Sao Paulo)[04/08226-9] Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Brazilian Foundation - FAPESP (Fundacao de Apoio a Pesquisa do Estado de Sao Paulo)[07/07139-3] CNPq[04113826-5] Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) INCT Complex Fluids Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) DECIT/Ministerio da Saude DECIT/Ministerio da Saude |
Identificador |
LABORATORY INVESTIGATION, v.90, n.5, p.685-695, 2010 0023-6837 http://producao.usp.br/handle/BDPI/28270 10.1038/labinvest.2010.45 |
Idioma(s) |
eng |
Publicador |
NATURE PUBLISHING GROUP |
Relação |
Laboratory Investigation |
Direitos |
restrictedAccess Copyright NATURE PUBLISHING GROUP |
Palavras-Chave | #mesenchymal stem cell #acute kidney injury #ischemia-reperfusion injury #fibrosis #inflammation #bone marrow #MESENCHYMAL STEM-CELLS #LONG-TERM OUTCOMES #MORPHOGENETIC PROTEIN-7 #MYCOPHENOLATE-MOFETIL #RENAL FIBROSIS #STROMAL CELLS #TUBULOINTERSTITIAL DAMAGE #INTERSTITIAL FIBROSIS #INTERFERON-GAMMA #GENE-EXPRESSION #Medicine, Research & Experimental #Pathology |
Tipo |
article original article publishedVersion |